Lilly France

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

Elpiscience Biopharmaceuticals Co., Ltd. operates as an immunology company that develops immunotherapies to treat cancer. The company is based in Pudong, China with an additional office in Suzhou, China.

ACEA Biosciences is a biotechnology company founded in 2002 and headquartered in San Diego, California. ACEA is a pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays. ACEA has a world-class manufacturing operation centered in Hangzhou, Zhejiang Province, China. The Life Technology Business Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology has been marketed globally under the xCELLigence brand. There are over 800 customers worldwide, and over 350 peer-reviewed publications using the xCELLigence technology. The newly launched iCELLigence instrument with wireless connectivity makes this innovative technology affordable to all users. In addition to the Life Technology Business Unit, ACEA also has a Therapeutics Business Unit which was launched in 2005. ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the platform biosensor technology and proprietary small molecule library (> 1 million compounds) to bring novel therapeutics into the clinic. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. With its international reach, ACEA Biosciences continues to work closely with scientists throughout the world to bring innovation to the R&D and health care industries.

Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategic partnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.

Transcenta Holding Ltd., a biotherapeutics company, engages in the research and development and manufacturing of antibody-based therapeutics. The company also offers clinical researches and trial services. Transcenta Holding Ltd. was founded in 2019 and is based in Suzhou, China. It has additional centers in Shanghai, Hangzhou, and Beijing, China; Waltham, Massachusetts; and Princeton, New Jersey.

Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

Transcenta Holding Ltd., a biotherapeutics company, engages in the research and development and manufacturing of antibody-based therapeutics. The company also offers clinical researches and trial services. Transcenta Holding Ltd. was founded in 2019 and is based in Suzhou, China. It has additional centers in Shanghai, Hangzhou, and Beijing, China; Waltham, Massachusetts; and Princeton, New Jersey.

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.

Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Mai Bosi is a focus on the development of biotechnology for the diagnosis and treatment of cancer, metabolic and autoimmune disease antibodies biotechnology company. The company has a barrier to break through the immune antibody development platform. This technology allows developers to effectively identify people get rat homologous epitope.

Terns Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops molecularly targeted, oral, small-molecule drugs to treat cancer and liver diseases. Its products includes TERN-101, a potent non-bile acid farnesoid X receptor agonist and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. The company was founded in 2017 and is based in Foster City, California with additional offices in Shanghai, China.

Beijing Targeting One Technology Co., Ltd. engages in the development and production of biomedical instruments, consumables, and in vitro diagnostic reagents for use in the fields of precision medicine, health management, and life science research. The company offers drop maker sample preparation apparatus, biochip readers, digital PCR supplies, ddPCR universal amplification reagents, micro-droplet generation and detection oils, genetic testing kits, and nucleic acid extraction reagents. Its digital PCR products have applications in the areas of transplant rejection monitoring, targeted sequencing, tumor liquid biopsy, and non-invasive prenatal screening. Beijing Targeting One Technology Co., Ltd. was founded in 2015 and is based in Beijing, China.

dMed Company Limited, also known as, dMed Biopharmaceutical Co., Ltd. operates as clinical contract research organization providing services for development of medicines and medical devices. The company offer services, including consulting, clinical operations, biostatistics & programming, data management, pharmacovigilance, clinical science & medical affairs, quality assurance, and regulatory affairs & Strategy. It serves biopharmaceutical and medical device companies. dMed Company Limited was founded in 2016 and is based in Shanghai, China.

Established in 2008, Geneseeq is an industry leader in Next-Generation Sequencing (NGS) fully committed to the research and clinical translation of NGS Genetic Sequencing in the field of personalized medicine. Geneseeq’s world-leading laboratories have successfully passed China’s National Center of Clinical Laboratories(NCCL) External Quality Assessment(EQA), College of American Pathologists(CAP) PT, European Molecular Genetics Quality Network(EMQN) PT, and received 3rd party medical laboratory and clinical PCR amplification laboratory qualifications.

InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.

Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer. The company's genetic technology can detect a wider range of variations in a gene than are typically found in next-generation sequencing and offers a screening test for hereditary breast and ovarian cancer risk, enabling clinical researchers and physicians in order to make informed decisions.

Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. Its lead drug development programs include two clinical-stage allosteric SHP2 inhibitors, including JAB-3068, a SHP2 inhibitor for the treatment of patients with solid tumor; and JAB-3312, an oral small molecule anti-tumor agent. The company was founded in 2015 and is based in Beijing, China. Jacobio Pharmaceuticals Co., Ltd. is a subsidiary of Jacobio (HK) Pharmaceuticals Co., Limited.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

Innovent Biologics, Inc. is a privately held biopharmaceutical company that is dedicated to the development and manufacturing of monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by the venture arm of Fidelity, which is a major investment firm in the US, Lilly Ventures, and Suzhou bioBay. The registered capital is 30Million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development and manufacture of biologics in the US, Europe and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.

Tmunity Therapeutics, Inc., a bio-therapeutics company, develops immunotherapies for cancer, infectious disease, and autoimmune disease treatment. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Insilico Medicine, an artificial intelligence company headquartered in Rockville, MD, pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning and meta-learning for generation of novel molecular structures for the diseases with known and unknown targets, and, unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

NuVera Medical, Inc. operates an imaging platform for cardiovascular procedures. The product uses 4D ultrasound technology to process the images. The product can be used by healthcare specialists for Intracardiac Echocardiography. NuVera Medical, Inc. was founded in 2016 and is based in Campbell, California.

Gritstone Oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. The company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer.

InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.

Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has unique advantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc.

Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

“To Translate Novel Modality into Reality”. Duality Biologics was founded in January 2020 by Dr. John Zhu, a well-respected investor in the healthcare industry. Duality Bio is committed to developing novel modality drugs to fulfill the unmet medical needs for patients worldwide. Focusing on the oncology and autoimmune diseases, the company has built a novel internal pipeline including nearly 10 Best-in-Class and First-in-Class bispecific antibody and Antibody-Drug Conjugate (ADC) drugs, of which several drug candidates are in the IND stage. The company has successfully built the next-generation ADC platform with global intellectual property rights. The value of this platform has been validated by a number of drug candidates under development.

360 Haoyao is an online pharmacy marketplace. 360 Haoyao is committed to creat a simple, convenient and trusted health product shopping experience. In order to safeguard its health, 360 Good Medicine connects the healthcare industry and relies on 360 strong technical capabilities to provide credible and feasible medical and e-commerce services, medical information services and "Internet +" technology solutions to Chinese Internet users and the pharmaceutical industry. Establish an industrial service system to promote the utilization of medical resources and promote the improvement of health management of all people.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Elpiscience Biopharmaceuticals Co., Ltd. operates as an immunology company that develops immunotherapies to treat cancer. The company is based in Pudong, China with an additional office in Suzhou, China.

Fountain Medical Development Ltd., a contract research organization, provides ICH GCP compliant clinical research services for the multinational clients in China and the United States. It offers consulting, project management, regulatory affairs, clinical operations, central laboratory services, site management, biometrics, and clinical trial designs, as well as AE/SAE collection, review, assessment and reporting services, data and safety monitoring board handling, and signal detection services. The company is based in Beijing, China.

Nuohui Health is an innovative bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes. Nuohui Health is committed to reducing the morbidity and mortality of cancer through biotechnological means. It first proposed the slogan of early cancer screening and is committed to promoting early cancer screening into thousands of households so that the public can enjoy convenient and efficient health services .

Mai Bosi is a focus on the development of biotechnology for the diagnosis and treatment of cancer, metabolic and autoimmune disease antibodies biotechnology company. The company has a barrier to break through the immune antibody development platform. This technology allows developers to effectively identify people get rat homologous epitope.

Sansure Biotech Inc. develops and sells upstream nucleic acid extraction kits, real time PCR diagnostic and research kits, and fluorescence systems in China and internationally. The company offers novel coronavirus nucleic acid diagnostic kits; viral hepatitis and AIDS, blood screening, and extraction kits; cancer-related biomarkers; and kits for respiratory tract diseases, STDs, digestive tract diseases, prenatal and postnatal care, and genetic diseases, as well as instruments and other consumables. It serves hospitals and laboratories. The company was founded in 2008 and is based in Changsha, China.

Ionova Life Science Co., Ltd. operates as a biotechnology company. The company engages in discovery and development of novel medicine for cancer treatment. It focuses on oncology, including immune-oncology and target delivery. The company uses its in-house build discovery platform for the development purpose. Ionova Life Science Co., Ltd. was founded in 2016 and is based in Shenzhen, China with additional offices in Hong Kong, Macao and Greater Bay Area.

IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more than four decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology.

Fountain Medical Development Ltd., a contract research organization, provides ICH GCP compliant clinical research services for the multinational clients in China and the United States. It offers consulting, project management, regulatory affairs, clinical operations, central laboratory services, site management, biometrics, and clinical trial designs, as well as AE/SAE collection, review, assessment and reporting services, data and safety monitoring board handling, and signal detection services. The company is based in Beijing, China.

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategic partnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products.

Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.

ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.

VIRTUE Diagnostics(Suzhou)Co.,Ltd. develops in vitro diagnostic platform. The company offers technology platforms including clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. VIRTUE Diagnostics(Suzhou)Co.,Ltd. was founded in 2019 and is based in Suzhou, China with a research and development office in Singapore.

VIRTUE Diagnostics(Suzhou)Co.,Ltd. develops in vitro diagnostic platform. The company offers technology platforms including clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. VIRTUE Diagnostics(Suzhou)Co.,Ltd. was founded in 2019 and is based in Suzhou, China with a research and development office in Singapore.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

“To Translate Novel Modality into Reality”. Duality Biologics was founded in January 2020 by Dr. John Zhu, a well-respected investor in the healthcare industry. Duality Bio is committed to developing novel modality drugs to fulfill the unmet medical needs for patients worldwide. Focusing on the oncology and autoimmune diseases, the company has built a novel internal pipeline including nearly 10 Best-in-Class and First-in-Class bispecific antibody and Antibody-Drug Conjugate (ADC) drugs, of which several drug candidates are in the IND stage. The company has successfully built the next-generation ADC platform with global intellectual property rights. The value of this platform has been validated by a number of drug candidates under development.

NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.

Singlera Genomics is a fast growing company focusing on non-invasive genetic testing. Singlera’s main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services. Singlera is dedicated to the development of precision medicine, striving to help the patients through early, accurate and informative diagnoses.

Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company.

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer. The company's genetic technology can detect a wider range of variations in a gene than are typically found in next-generation sequencing and offers a screening test for hereditary breast and ovarian cancer risk, enabling clinical researchers and physicians in order to make informed decisions.

IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more than four decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology.

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.

Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

ReadCoor, Inc. develops and commercializes a panomic spatial sequencing platform for researchers, clinicians, pharmaceutical and diagnostics companies, and patients worldwide. It offers FISSEQ, a platform that enables integration of high throughput sequencing, morphometric analysis, cellular location, and three-dimensional spatial imaging. The company’s platform also enables researchers to perform RNA-Seq while preserving sample morphology and simultaneously providing cellular location and spatial image data. ReadCoor, Inc. was incorporated in 2016 and is based in Cambridge, Massachusetts. As of October 13, 2020, ReadCoor, Inc. operates as a subsidiary of 10x Genomics, Inc.

“Peijia Medical” was established in early 2012, by returned oversea Chinese expert in professional medical device industry, providing R&D and production of interventional medical products. The company with register capital of RMB￥30 million is located in Suzhou Industrial Park, Suzhou city of Jiangsu Province. The city of Suzhou is famously named as "earthly paradise in China" and the Industrial Park beside Jinji Lake is called as “new paradise of venture capital investment”. The company covers an area of about 10000 sqm, within which laboratory and controlled environment room taking about 1800 sqm. The company has state of the art interior design with western high tech modern style infused with Suzhou oriental garden style. The office building, laboratory, and controlled environment production rooms are fully put into operation now.

Transcenta Holding Ltd., a biotherapeutics company, engages in the research and development and manufacturing of antibody-based therapeutics. The company also offers clinical researches and trial services. Transcenta Holding Ltd. was founded in 2019 and is based in Suzhou, China. It has additional centers in Shanghai, Hangzhou, and Beijing, China; Waltham, Massachusetts; and Princeton, New Jersey.

Innovent Biologics, Inc. is a privately held biopharmaceutical company that is dedicated to the development and manufacturing of monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by the venture arm of Fidelity, which is a major investment firm in the US, Lilly Ventures, and Suzhou bioBay. The registered capital is 30Million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development and manufacture of biologics in the US, Europe and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.

Fountain Medical Development Ltd., a contract research organization, provides ICH GCP compliant clinical research services for the multinational clients in China and the United States. It offers consulting, project management, regulatory affairs, clinical operations, central laboratory services, site management, biometrics, and clinical trial designs, as well as AE/SAE collection, review, assessment and reporting services, data and safety monitoring board handling, and signal detection services. The company is based in Beijing, China.

Lynk Pharmaceuticals (Hangzhou) Co., Ltd. is engaged in the development of small molecule drugs for tumors and autoimmune diseases through new drug research, sales, patent authorization and patent transfer. The firm was founded in 2017 and is headquartered in China.

KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd. develops and commercializes novel cancer immunotherapy products. The company designs platforms to reverse cancer cell-induced immune inhibition and to eradicate cancer cells. It offers platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells to fulfill the cancer-killing task. The company’s platforms include Target-Activated NK (TANK™) Cell Therapy, PD-1/PD-L1 antibody blockade assay platform, and Activating Macrophages. The company was founded in 2015 and is headquartered in Shanghai, China.

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired and functional protein is restored. It was founded in 2019 and is headquartered in San Diego, California.

Ionova Life Science Co., Ltd. operates as a biotechnology company. The company engages in discovery and development of novel medicine for cancer treatment. It focuses on oncology, including immune-oncology and target delivery. The company uses its in-house build discovery platform for the development purpose. Ionova Life Science Co., Ltd. was founded in 2016 and is based in Shenzhen, China with additional offices in Hong Kong, Macao and Greater Bay Area.

NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.

Fountain Medical Development Ltd., a contract research organization, provides ICH GCP compliant clinical research services for the multinational clients in China and the United States. It offers consulting, project management, regulatory affairs, clinical operations, central laboratory services, site management, biometrics, and clinical trial designs, as well as AE/SAE collection, review, assessment and reporting services, data and safety monitoring board handling, and signal detection services. The company is based in Beijing, China.

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China and internationally. It offers infusion and non-infusion products, and new injection package. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.

IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more than four decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology.

Fortis Therapeutics is an immuno-oncology biotech focused on developing new antibody drug conjugate therapies for late-stage multiple myeloma and late-stage prostate cancer. Fortis Therapeutics was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.

ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd. develops and commercializes novel cancer immunotherapy products. The company designs platforms to reverse cancer cell-induced immune inhibition and to eradicate cancer cells. It offers platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells to fulfill the cancer-killing task. The company’s platforms include Target-Activated NK (TANK™) Cell Therapy, PD-1/PD-L1 antibody blockade assay platform, and Activating Macrophages. The company was founded in 2015 and is headquartered in Shanghai, China.

Shanghai MediTrust Health Technology Co., Ltd. provides help to patients solve its medical expenses through financial insurance. The firm is based in Shanghai, China.

Insilico Medicine, an artificial intelligence company headquartered in Rockville, MD, pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning and meta-learning for generation of novel molecular structures for the diseases with known and unknown targets, and, unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products.

dMed Company Limited, also known as, dMed Biopharmaceutical Co., Ltd. operates as clinical contract research organization providing services for development of medicines and medical devices. The company offer services, including consulting, clinical operations, biostatistics & programming, data management, pharmacovigilance, clinical science & medical affairs, quality assurance, and regulatory affairs & Strategy. It serves biopharmaceutical and medical device companies. dMed Company Limited was founded in 2016 and is based in Shanghai, China.

Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.

Rongchang Pharmaceutical has grown into a modern pharmaceutical company enterprise integrating the r$d,production and sales of modern chinese medicine and biological drugs.

Tmunity Therapeutics, Inc., a bio-therapeutics company, develops immunotherapies for cancer, infectious disease, and autoimmune disease treatment. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, develops clinical candidates for cardiovascular, metabolic, and kidney diseases. It focuses on developing CIN-107, a aldosterone synthase inhibitor for the treatment of resistant hypertension and primary aldosteronism. The company was founded in 2018 and is based in Cincinnati, Ohio.

Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.

Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Hopstem Biotechnology LLC specializes in neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells and human embryonic stem cells. It offers its technologies to promote biomedical research, diagnoses, and therapies of neurological and other disorders. The company was incorporated in 2019 and is headquartered in Houston, Texas.

Zentera Therapeutics is a biopharmaceutical company.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has unique advantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc.

Terns Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops molecularly targeted, oral, small-molecule drugs to treat cancer and liver diseases. Its products includes TERN-101, a potent non-bile acid farnesoid X receptor agonist and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. The company was founded in 2017 and is based in Foster City, California with additional offices in Shanghai, China.

InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

Dizal Pharmaceutical is a research-based biotechnology company dedicated to the discovery, development, and commercialization of first-in-class/best-in-class medicines.

Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus. The company was founded in 2003 and is headquartered in San Diego, California.

Beida Pharmaceutical Co., Ltd. is a state-level high-tech pharmaceutical company founded by the team of Dr. Haigui, with research and development of independent intellectual property and innovative drugs as its core, integrating R&D, production and marketing. The company has always been committed to the research and development and production of new types of drugs in the country with independent intellectual property rights.

ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.

Transcenta Holding Ltd., a biotherapeutics company, engages in the research and development and manufacturing of antibody-based therapeutics. The company also offers clinical researches and trial services. Transcenta Holding Ltd. was founded in 2019 and is based in Suzhou, China. It has additional centers in Shanghai, Hangzhou, and Beijing, China; Waltham, Massachusetts; and Princeton, New Jersey.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..

Elpiscience Biopharmaceuticals Co., Ltd. operates as an immunology company that develops immunotherapies to treat cancer. The company is based in Pudong, China with an additional office in Suzhou, China.

Fortis Therapeutics is an immuno-oncology biotech focused on developing new antibody drug conjugate therapies for late-stage multiple myeloma and late-stage prostate cancer. Fortis Therapeutics was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.

Sonoma Pharmaceuticals is a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 33 countries. The company’s products, over 100 SKUs commercialized worldwide, are used to treat patients in advanced wound management, dermatology, women’s health and animal health; addressing the unmet medical needs of these markets—while raising the standard of patient care and lowering overall healthcare costs.

NuVera Medical, Inc. operates an imaging platform for cardiovascular procedures. The product uses 4D ultrasound technology to process the images. The product can be used by healthcare specialists for Intracardiac Echocardiography. NuVera Medical, Inc. was founded in 2016 and is based in Campbell, California.

Pulnovo Medical integrates development, production and services. Our core products including use pf radiofrequency ablation technology to treat pulmonary hypertension. The high-frequency ablation equipment and intravascular catheters developed by the company are pioneer inventions with global invention patents.

SciNeuro Pharmaceuticals develops medicines for patients with central nervous system (CNS) diseases. The company is based in Shanghai, China.

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.

InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

Tmunity Therapeutics, Inc., a bio-therapeutics company, develops immunotherapies for cancer, infectious disease, and autoimmune disease treatment. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.

Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus. The company was founded in 2003 and is headquartered in San Diego, California.

Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.

IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more than four decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology.

HD Biosciences Inc. (HDB) is a Shanghai-based biotech company specializing in drug discovery contract research. HDB has developed extensive knowledge and comprehensive technology platforms for drug discovery including assay development, high throughput drug screening, SAR, closed-loop and hit-to-lead biology solutions, as well as natural product-based lead discovery. The Company has signed multiple-year research agreements with clients including Pfizer, Organon and other pharmaceutical and biotech clients and is an indisputable leader in high value-added biology-based drug discovery CRO business in China.

ACEA Biosciences is a biotechnology company founded in 2002 and headquartered in San Diego, California. ACEA is a pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays. ACEA has a world-class manufacturing operation centered in Hangzhou, Zhejiang Province, China. The Life Technology Business Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology has been marketed globally under the xCELLigence brand. There are over 800 customers worldwide, and over 350 peer-reviewed publications using the xCELLigence technology. The newly launched iCELLigence instrument with wireless connectivity makes this innovative technology affordable to all users. In addition to the Life Technology Business Unit, ACEA also has a Therapeutics Business Unit which was launched in 2005. ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the platform biosensor technology and proprietary small molecule library (> 1 million compounds) to bring novel therapeutics into the clinic. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. With its international reach, ACEA Biosciences continues to work closely with scientists throughout the world to bring innovation to the R&D and health care industries.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..

Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..

IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more than four decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology.

Singlera Genomics is a fast growing company focusing on non-invasive genetic testing. Singlera’s main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services. Singlera is dedicated to the development of precision medicine, striving to help the patients through early, accurate and informative diagnoses.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

Legend Biotech is a biopharmaceutical company bringing impactful innovations in cell therapy, and accelerating the science. They are committed to improving the lives of patients worldwide. They are also steadfast in their goal to develop innovative cellular therapies that bring us closer to a cure. It develops cell therapies from discovery through commercialization.

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.

CrownBio is a Cutting Edge Translational Technology Company Making Precision Medicine a Reality CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, cardiovascular, and metabolic disease Drug Discovery. Their premier Translational Platforms for cancer and metabolic disease help our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. They are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan.

Burning Rock focuses on providing individualized cancer treatment guidance for the patients. Using medical and bio informatics plus Next-Generation Sequencing (NGS) as the core technologies, the company is committed to offering one-stop solution for clinical and R&D services concerning the genetic testing of individualized cancer treatment. Established in March 2014, Burning Rock is headquartered in Beijing. Its first medical laboratory, "Guangzhou Burning Rock Medical Examination Institute Co., Ltd." is situated on Guangzhou International Bio Island which is blessed with a picturesque environment and rich in scientific research deposits. Later it established a R&D center in Shanghai. It occupies over 10,000 ㎡ in total. Burning Rock is committed to guiding the individualistic treatment of tumor patients, centered around NGS and biomedical informatics, with conventional tumor molecular pathology detection as the cornerstone, trying to build one-stop solutions for individualistic treatment clinical detection service and scientific research of tumor.

Regor Therapeutics is a clinical-stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, seamlessly integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. Regor has assembled a world-class scientific team and demonstrated high efficiency in producing best- and first-in-class molecules.

CARsgen Therapeutics, Ltd., a clinical-stage immunotherapy company, develops and commercializes chimeric antigen receptor T-cell (CAR-T) therapeutics for treating cancers. It offers CAR-T Technology that directs T cells to recognize cancer cells based on expression of specific cell surface proteins to treat solid and hematologic tumors. The company’s CAR-T cells target the GPC3 receptor for the treatment of late-stage hepatocellular carcinoma (HCC, or liver cancer) and lung squamous cell carcinoma (a common type of lung cancer). CARsgen Therapeutics, Ltd. is based in Shanghai, China.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

Terns Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops molecularly targeted, oral, small-molecule drugs to treat cancer and liver diseases. Its products includes TERN-101, a potent non-bile acid farnesoid X receptor agonist and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. The company was founded in 2017 and is based in Foster City, California with additional offices in Shanghai, China.

Innovent Biologics, Inc. is a privately held biopharmaceutical company that is dedicated to the development and manufacturing of monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by the venture arm of Fidelity, which is a major investment firm in the US, Lilly Ventures, and Suzhou bioBay. The registered capital is 30Million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development and manufacture of biologics in the US, Europe and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.

Elpiscience Biopharmaceuticals Co., Ltd. operates as an immunology company that develops immunotherapies to treat cancer. The company is based in Pudong, China with an additional office in Suzhou, China.

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

360 Health provide health care and life science services to clients in China.

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

“Peijia Medical” was established in early 2012, by returned oversea Chinese expert in professional medical device industry, providing R&D and production of interventional medical products. The company with register capital of RMB￥30 million is located in Suzhou Industrial Park, Suzhou city of Jiangsu Province. The city of Suzhou is famously named as "earthly paradise in China" and the Industrial Park beside Jinji Lake is called as “new paradise of venture capital investment”. The company covers an area of about 10000 sqm, within which laboratory and controlled environment room taking about 1800 sqm. The company has state of the art interior design with western high tech modern style infused with Suzhou oriental garden style. The office building, laboratory, and controlled environment production rooms are fully put into operation now.

Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.